The American College of Cardiology (ACC) https://www.acc.org is leveraging AI-based predictive analytics and virtual health navigators for ACC’s TRANSFORM (3) study and has just announced that the Biofourmis https://Biofourmis.com care solution has been selected by ACC for their study.
In the U.S, heart failure affects an estimated 6 million Americans. Poor heart failure management is the leading cause of hospitalizations and readmissions among older adults. However, only 25% of eligible patients receive Guideline Directed Medication Therapy (GDMT) and less than 1% are titrated to optimal doses.
The study “Evaluation of Implementation Strategies of Teaching, Technology, and Teams to Optimize Medical Therapy in Cardiovascular Disease (T3)” will include participants with cardiovascular conditions especially in underserved patients with the current emphasis on ongoing clinical validation of Artificial Intelligence and AI-based virtual care solutions.
The study will focus on populations with a history of healthcare disparities in order to evaluate different intervention strategies for improving adherence to GDMT for managing specific chronic cardiovascular conditions.
The ACC study using the Biofourmis Care Platform has three arms:
- One arm focuses on patient education only
- One arm leverages the Biofourmis Care solution—including connected devices and medication optimization algorithms with patient management by local providers
- One arm also uses the Biofourmis Care solution + Biofourmis’ frontline virtual health navigators
“ACC’s selection of Biofourmis to take part in the TRANSFORM study signifies a growing recognition in healthcare that virtual care modalities need to be evaluated as viable and clinically prudent alternatives to more costly and time consuming in person clinic visits for management of patients with complex chronic conditions” said, Maulik Majmudar, MD,CMO and Co-Founder of Biofourmis.
He continued to say, “By the study’s conclusion, we are confident that the complete Biofourmis Care solution, including our licensed multidisciplinary care teams ability to focus on optimization of guideline directed medical therapies, will demonstrate superior performance as compared with the current standards of care.”